Reign Resources (OTCMKTS:RGNP) Decreases Authorized Common Stock in Recent Filing

Reign Resources (OTCMKTS:RGNP) recently made a significant amendment to its corporate structure by reducing its authorized common stock. According to a filing submitted to the Securities and Exchange Commission on December 30, 2024, the company successfully filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware.

The amendment, which took immediate effect upon filing, saw Reign Resources decrease its authorized common stock to One Hundred Million (100,000,000) shares, each with a par value of $0.0001. In contrast, the authorized preferred stock remained unchanged at Ten Million (10,000,000) shares with a par value of $0.0001.

This alteration is expected to impact the company’s financial structure and potentially influence future business decisions and strategies moving forward.

The filing also included the submission of necessary exhibits, namely the Certificate of Amendment to Amended and Restated Certificate of Incorporation filed on December 30, 2024, along with the Cover Page Interactive Data File.

James A. Joyce, the Chairman and CEO of Reign Resources, signed the filing on behalf of the company as required by the Securities and Exchange Act of 1934. The report was officially signed on January 6, 2025.

Investors and stakeholders may want to keep a close watch on Reign Resources following this recent amendment to its corporate structure, as it could signal changes in the company’s operations and future endeavors.

Reference: SEC Filing for Reign Resources (OTCMKTS:RGNP) on December 30, 2024.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Reign Resources’s 8K filing here.

Reign Resources Company Profile

Sigyn Therapeutics, Inc operate as development-stage therapeutic technology company. It focuses on the treatment of life-threatening inflammatory conditions that are precipitated by cytokine storm syndrome. The company was founded by James A. Joyce and Craig P. Roberts and is headquartered in San Diego, CA.